FilingReader Intelligence
Huahai Pharma boosts stockholder returns, plans new debt funding
April 30, 2025 at 06:03 AM UTC•By FilingReader AI
Zhejiang Huahai Pharmaceutical (SSE:600521) announced plans to increase shareholder returns by proposing a cash dividend of CNY 0.25 per share for 2024. This decision, detailed in the 2024 Annual Audit Report, reflects the company's strong financial performance, with profits attributable to shareholders reaching CNY 1,118.98 million. The dividend proposal will go to the shareholders for a vote.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Special audit statement on the occupation of non-operating funds and other related-party fund transactions of Zhejiang Huahai Pharmaceutical Co., Ltd.April 29, 2025 at 02:24 PM UTC
Announcement of Zhejiang Huahai Pharmaceutical Co., Ltd.'s 2024 Profit Distribution PlanApril 29, 2025 at 02:24 PM UTC
Zhejiang Huahai Pharmaceutical Co., Ltd. Announcement on Changes in Accounting PoliciesApril 29, 2025 at 02:24 PM UTC
Zhejiang Huahai Pharmaceutical Co., Ltd. Announcement on Cancelling Part of the Repurchased Shares and Reducing the Registered CapitalApril 29, 2025 at 02:24 PM UTC
Zhejiang Huahai Pharmaceutical Co., Ltd.'s announcement on the company's application for comprehensive credit line and provision of guarantee from banks in 2025April 29, 2025 at 02:24 PM UTC
Zhejiang Huahai Pharmaceutical Co., Ltd. 2024 Annual Report SummaryApril 29, 2025 at 02:24 PM UTC
Zhejiang Huahai Pharmaceutical Co., Ltd. Announcement on the Reappointment of Accounting FirmApril 29, 2025 at 02:24 PM UTC
Zhejiang Huahai Pharmaceutical Co., Ltd.'s announcement on the cancellation of the board of supervisors, change of registered address, amendment of the company's articles of association, and formulation and amendment of some internal governance systemsApril 29, 2025 at 02:24 PM UTC
Zhejiang Huahai Pharmaceutical Co., Ltd. 2024 Internal Control Evaluation ReportApril 29, 2025 at 02:24 PM UTC
Internal Control Audit Report of Zhejiang Huahai Pharmaceutical Co., Ltd.April 29, 2025 at 02:24 PM UTC
Special review opinion of Zheshang Securities Co., Ltd. on the deposit and actual use of raised funds of Zhejiang Huahai Pharmaceutical Co., Ltd. in 2024April 29, 2025 at 02:24 PM UTC
Zhejiang Huahai Pharmaceutical Co., Ltd.'s announcement on the provision for asset impairment in 2024April 29, 2025 at 02:24 PM UTC
Zhejiang Huahai Pharmaceutical Co., Ltd. 2024 Annual ReportApril 29, 2025 at 02:24 PM UTC
Zhejiang Huahai Pharmaceutical Co., Ltd.'s announcement on launching foreign exchange derivatives trading business in 2025April 29, 2025 at 02:24 PM UTC
Zhejiang Huahai Pharmaceutical Co., Ltd.'s announcement on canceling part of the repurchased shares to reduce the registered capital and notifying creditorsApril 29, 2025 at 02:24 PM UTC
Zhejiang Huahai Pharmaceutical Co., Ltd.'s special report on the deposit and actual use of raised funds in 2024April 29, 2025 at 02:24 PM UTC
Zhejiang Huahai Pharmaceutical Co., Ltd. 2025 First Quarter ReportApril 29, 2025 at 02:24 PM UTC
Announcement of Resolutions of the Third Meeting of the Eighth Board of Directors of Zhejiang Huahai Pharmaceutical Co., Ltd.April 29, 2025 at 02:24 PM UTC
News Alerts
Get instant email alerts when Zhejiang Huahai Pharmaceutical publishes news
Free account required • Unsubscribe anytime